Answers are grounded in this paper and cite their sources.
Comparative review examines the effectiveness, limitations, and costs of incretin therapies and metabolic bariatric surgery for obesity, highlighting evolving care pathways and clinical evidence gaps.
Incretin-based therapies are increasingly used for obesity management, raising debate about whether they could challenge or replace metabolic bariatric surgery (MBS). Here, we compare evidence for both treatments, focusing on effectiveness, limitations and costs. We also explore how obesity care pathways may evolve and highlight key evidence gaps that must be addressed to define the future roles of incretin-based therapies and MBS in obesity management.
No takes yet. Share an insight, caveat, or question.
Christmas et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: